AAPG Ascentage Pharma Group Internat

Half year earnings put Ascentage Pharma Group International (SEHK:6855) losses in focus Ascentage Pharma Group International (SEHK:6855) released half year earnings to June 30, 2026, reporting sales of CNY 302.21 million and a net loss of CNY 816.69 million, with a basic loss per share of CNY 2.19. Ascentage Pharma Group International’s recent half year results arrived alongside a sharp move in the stock, with a 1 day share price return of 12.08% and a 7 day share price return of 9.88% at...

Moby summary of ASCENTAGE PHARMA GROUP INTERNATIONAL's Q2 2026 earnings call

Ascentage Pharma Group International (NASDAQ:AAPG) reported first-half 2026 revenue growth as it continued investing in global registrational studies for its hematology-oncology pipeline and began building commercial capabilities outside China. Total revenue for the six months ended June 30 was $44

The average of price targets set by Wall Street analysts indicates a potential upside of 160.1% in Ascentage Pharma Group International - Unsponsored ADR (AAPG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The consensus price target hints at a 152.2% upside potential for Ascentage Pharma Group International - Unsponsored ADR (AAPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.